Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAdTetra
- Development stage
- Preclinical
- Lead developer
- Baylor College of Medicine
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
CAdTetra is a binary oncolytic/helper-dependent adenovirus system (CAdVEC) developed by researchers at the Baylor College of Medicine. It is designed to enhance local and systemic antitumor immunity against solid tumors, including cancer stem cell populations. CAdTetra is built upon the CAdTrio platform, which co-expresses interleukin-12 (IL-12), a programmed death-ligand 1 (PD-L1) blocker, and a herpes simplex virus thymidine kinase (HSV-tk) safety switch. CAdTetra additionally incorporates a bispecific T-cell engager (BiTE) targeting CD44v6. This design redirects tumor-infiltrating, virus-specific (or other irrelevant) T cells to target and eliminate CD44v6-expressing cancer stem cells, thereby overcoming the immunosuppressive tumor microenvironment and inducing robust adaptive antitumor immune responses.
- Other names
- CD44v6.BiTE-expressing CAdVECCD-44v6.BiTE-expressing CAdVECCD 44v6.BiTE-expressing CAdVECCD44v6.bispecific T-cell engager + CAdTrio
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD44v6 (CD44 variant isoform 6)IL-12R (Interleukin-12 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on CAdTetra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAdTetra.